Atea Pharmaceuticals, Inc. AVIR
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is an infectious disease drug developer. Its lead program, bemnifosbuvir/ruzasvir (BEM/RZR), is in Phase 3 for Chronic hepatitis C. Its next catalyst on record is BEM/RZR: C-FORWARD Phase 3 topline results (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: BEM/RZR — C-FORWARD Phase 3 topline results (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BEM/RZR | HCV | small molecule | Phase 3 |
| AT-587 | Chronic HEV | small molecule | Phase 1 |
Recent results and decisions
- Aug 12, 2026met Phase 3 C-BEYOND met primary non-inferiority endpoint: 93.9% SVR for BEM/RZR vs 94.8% for SOF/VEL (mITT, n=905); topline first announced in July.
The trial achieved its primary endpoint of statistical non-inferiority, with a 95% confidence interval for difference in SVR rates within the prespecified 5% margin.
Filing - Aug 12, 2026completed enrollment C-FORWARD Phase 3 enrollment completed in June 2026 with more than 880 patients across 17 countries.
Patient enrollment for C-FORWARD was completed in June 2026 with more than 880 patients across 17 countries.
Filing - Jan 8, 2026completed enrollment C-BEYOND Phase 3 fully enrolled with over 880 patients.
C-BEYOND is fully enrolled with over 880 patients, with topline results expected mid-2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 infectious disease companies
- Gilead Sciences, Inc. GILD
- GSK plc GSK
- Moderna, Inc. MRNA
- Vaxcyte, Inc. PCVX
- Vir Biotechnology, Inc. VIR
- Novavax Inc NVAX
- Sinovac Biotech Ltd SVA
- CorMedix Inc. CRMD
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.